Rosacea Treatment Guidelines

Introduction to Rosacea Treatment

The American Academy of Dermatology recommends initiating topical ivermectin 1% cream once daily as first-line therapy for mild to moderate inflammatory rosacea, demonstrating superior efficacy and longer time to relapse compared to other topical agents 1
Topical ivermectin 1% cream shows clinical improvement within 3-4 weeks, with full assessment requiring 6-12 weeks 1

For mild inflammatory papules/pustules, the American Academy of Dermatology suggests starting with topical ivermectin 1% cream once daily as the most effective first-line option 1, 2
Alternative first-line agents include topical azelaic acid 15% gel or foam once daily, topical metronidazole 0.75% or 1.0% once daily, and encapsulated benzoyl peroxide 5% cream once daily 1, 2
For moderate inflammatory disease, the British Association of Dermatologists recommends combining topical ivermectin 1% cream once daily with oral doxycycline 40 mg modified-release daily for more rapid control 1, 2

The American Academy of Dermatology suggests adding topical brimonidine tartrate 0.33% gel once daily for persistent facial erythema, which provides rapid vasoconstriction with maximal effects between 3-6 hours after application 1, 2
Alternative: Oxymetazoline HCl 1% cream once daily, with composite success rates of 12.3-14.8% at 12 hours 1

Ivermectin demonstrates clear superiority over other topical treatments, with an 83% reduction in lesion counts vs. 73.7% with metronidazole 0.75% 1
Ivermectin shows longer time to relapse: 115 days vs. 85 days with metronidazole 1, 2

The American Academy of Dermatology recommends using multiple cutaneous features require simultaneous treatment with different agents, such as ivermectin 1% cream for papules/pustules plus brimonidine 0.33% gel for erythema, which provides additive benefits without significant side effects 1, 2

Without maintenance therapy, up to two-thirds of patients will relapse when treatment is discontinued, and the American Academy of Dermatology suggests continuing topical therapy indefinitely using the minimum treatment necessary to maintain control 1, 2
Ivermectin provides the most durable response among topical treatments, with maintenance of efficacy for up to 52 weeks 1

The American Academy of Dermatology recommends applying broad-spectrum sunscreen SPF 30+ daily, as UV exposure is a major rosacea trigger 1, 2
Using gentle, non-irritating cleansers specifically formulated for sensitive skin is essential, as well as applying moisturizers appropriate for sensitive skin 1, 2

For children under 8 years, the American Academy of Pediatrics recommends using oral erythromycin instead of tetracyclines due to permanent tooth staining risk 3
First-line for mild disease: Topical metronidazole 0.75% or 1.0% once daily, and moderate to severe disease: Combination of topical agent (ivermectin, metronidazole, or azelaic acid) plus oral erythromycin 3

The American Academy of Ophthalmology recommends using a stepwise approach based on severity, with mild cases: Lid hygiene measures, and moderate to severe cases: Oral doxycycline 40 mg daily (or erythromycin in children <8 years) combined with lid hygiene 3, 2

Discontinuing therapy before 6-8 weeks prevents adequate assessment of efficacy, and up to 89% of patients who experience treatment-related adverse effects discontinue therapy within a month 1
Not addressing erythema separately with vasoconstrictors, as anti-inflammatory agents do not improve fixed vascular changes, and overlooking combination therapy for moderate and severe presentations, as monotherapy is often insufficient 1
Never use tetracyclines in children under 8 years due to permanent tooth staining, and avoid standard acne treatments (tretinoin, adapalene) as these are not indicated for rosacea and may worsen symptoms 4, 3, 2

Oxymetazoline is a topical α1-receptor agonist that vasoconstricts vascular smooth muscle, thereby diminishing the appearance of facial redness in patients with rosacea, as indicated by the FDA for the treatment of persistent facial erythema 5

The FDA approval of oxymetazoline was based on two phase 3, 8-week, double-blind, randomized placebo-controlled trials involving 885 subjects with moderate-to-severe constant central facial redness, demonstrating composite success rates of 12.3-14.8% at 12 hours 5, 6
Composite success rate (≥2-grade improvement by both clinician and patient assessment) at day 29, hour 12, was 14.8% (study 1) and 12.3% (study 2) versus 6.0-6.1% with vehicle, in patients with moderate-to-severe rosacea 5, 6
Digital photographic assessments at 3 hours showed a 25% median reduction in redness, diminishing to 9.6-14.8% at 12 hours, in patients treated with oxymetazoline 5, 6

Oxymetazoline demonstrates excellent long-term safety with minimal discontinuation rates, with only 3.2% of subjects discontinuing due to application-site adverse events during 52-week treatment, in patients with rosacea 5, 6
Fewer than 1% of withdrawals were due to treatment-related adverse events in extended studies of oxymetazoline 7
No rosacea flares, no increases in papules or pustules, and no worsening of telangiectasias were observed with oxymetazoline treatment 5, 6
No tachyphylaxis was reported with long-term use of oxymetazoline 5, 6

Unlike brimonidine, oxymetazoline does not carry the same risk of paradoxical erythema, which affects 10-20% of brimonidine users, making it a suitable alternative for patients with rosacea 7
Oxymetazoline 1% cream has a sustained 12-hour effect and is administered once daily, compared to brimonidine 0.33% gel, which has a faster onset but a higher risk of paradoxical erythema 5, 6, 7